Nurix Therapeutics (NRIX) Interest Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Interest Expenses data on file, last reported at $400000.0 in Q2 2026.

• On a quarterly basis, Interest Expenses fell 20.0% year-over-year to $400000.0 in Q2 2026; TTM through May 2026 was $3.0 million, a 39.09% decrease from a year earlier, with the FY2025 full-year figure at $331.2 million, up 45.86% from the prior year.
• Interest Expenses for Q2 2026 stood at $400000.0, down from $775000.0 in the prior quarter.
• Over the last five years, Interest Expenses for NRIX reached as high as $49.5 million in Q2 2022 and fell as low as $100000.0 in Q3 2024.
• Historically, Interest Expenses has averaged $8.2 million across 5 years, with a median of $1.4 million in 2023.
• On a YoY basis, Interest Expenses climbed as much as 102.25% in 2023 and fell as far as 97.68% in 2023.
• Year by year, Interest Expenses stood at $1.4 million in 2022, then jumped by 102.25% to $2.8 million in 2023, then slipped by 23.22% to $2.1 million in 2024, then dropped by 20.39% to $1.7 million in 2025, then tumbled by 76.55% to $400000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $400000.0 in Q2 2026, $775000.0 in Q1 2026, and $1.7 million in Q4 2025.